Eli Lilly signed a multi‑year collaboration with Nvidia to build an AI laboratory for drug discovery and development, committing up to $1 billion over five years. The partnership will combine Lilly’s drug discovery capabilities with Nvidia’s AI infrastructure and chipsets to accelerate computational chemistry, biomarker discovery and model training at scale. The pact follows earlier cloud and supercomputing investments in pharma and reflects how leading drugmakers are outsourcing heavy compute and model training to chip providers. The agreement is positioned to speed preclinical hypothesis testing and reduce timelines for candidate selection by scaling generative and predictive AI workflows.